Lung Neuroendocrine Carcinoma — Trials

Lung Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 389
Recruiting: 206
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (158)

clinicaltrialsPublishedShowing 101–150 of 1,113 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06745323	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309)	active not recruiting	Phase 2	252	AmgenINDUSTRY	16	Aug 17, 2026	clinicaltrials
NCT06768307	Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer	recruiting	Phase 2	60	Peking University Cancer Hospital & InstituteOTHER	1